Not Yet RecruitingNot Applicable

Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion

100 participantsStarted 2026-05

Plain-language summary

The purpose of this study is to evaluate the real-world performance, safety and efficacy of the TRAQ System.

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age and Body Mass Index (BMI)
✓. Adult patients aged ≥ 21 years at screening.
✓. BMI ≤ 40.
✓. Chronic SIJ Related Pain
✓. Has experienced low back and/or buttock pain for at least 6 months that has been inadequately responsive to non surgical management.
✓. Has experienced nonradicular pain that is maximal below the L5 vertebrae, localized over the posterior SIJ, and consistent with SIJ pain.
✓. Diagnosis of SIJ Dysfunction
✓. Baseline Disability and Pain Severity

✕. Pain Source Uncertainty
✕. Alternative Primary Spine Pathology
✕. Other Sacroiliac Pathology a. Presence of known sacroiliac joint pathology other than degenerative SIJ dysfunction, including inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA associated spondyloarthropathies), tumor, infection, acute fracture, or crystal arthropathy.
✕. Non SIJ Pain Syndromes
✕. Recent Sacral Interventions
✕. Recent Pelvic Trauma
✕. Severe Osteoporosis
✕. Medications Affecting Bone or Soft Tissue Healing

Composite safety and efficacy endpoint

Timeframe: Month 6

NCT IDNCT07547215

SponsorPainTEQ, LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-12

Lalit Venkatesan, PhD